Manager × security

Michelson Medical Research Foundation, Inc. VEA holdings history

VANGUARD FTSE DEVELOPED ETF · CUSIP 921943858 · CIK 1965304

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Michelson Medical Research Foundation, Inc. reported 158.16K VEA (shares), valued at $11.27M, or 10.41% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
10.41%
Shares
158.16K
158,160
Reported value
$11.27M
USD

Shares unchanged; reported value increased 11.19%, and weight changed +0.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 202610.41%158,160SEC filing ↗Filed Aug 14, 2026
Q1 202610.29%158,160SEC filing ↗Filed May 15, 2026
Q4 20259.90%158,160SEC filing ↗Filed Feb 17, 2026
Q3 20258.24%158,160SEC filing ↗Filed Nov 14, 2025
Q2 20258.65%158,160SEC filing ↗Filed Aug 14, 2025
Q1 20256.73%158,160SEC filing ↗Filed May 15, 2025
Q4 20246.34%158,160SEC filing ↗Filed Feb 14, 2025
Q3 202413.45%361,160SEC filing ↗Filed Nov 14, 2024
Q2 202415.35%361,160SEC filing ↗Filed Aug 14, 2024
Q1 202410.98%361,160SEC filing ↗Filed May 15, 2024
Q4 20234.81%361,160SEC filing ↗Filed Feb 14, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20234.81%361,160$7.30MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 14, 2024
Q1 202410.98%361,160$18.12MShares unchanged; reported value increased 148.23%, and weight changed +6.17 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 202415.35%361,160$17.85MShares unchanged; reported value decreased 1.49%, and weight changed +4.37 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 202413.45%361,160$19.07MShares unchanged; reported value increased 6.86%, and weight changed -1.90 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20246.34%158,160$7.56MShares decreased 56.21%; reported value decreased 60.35%, and weight changed -7.11 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20256.73%158,160$8.04MShares unchanged; reported value increased 6.29%, and weight changed +0.39 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20258.65%158,160$9.02MShares unchanged; reported value increased 12.16%, and weight changed +1.92 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20258.24%158,160$9.48MShares unchanged; reported value increased 5.10%, and weight changed -0.41 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20259.90%158,160$9.88MShares unchanged; reported value increased 4.26%, and weight changed +1.66 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 202610.29%158,160$10.13MShares unchanged; reported value increased 2.58%, and weight changed +0.39 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 202610.41%158,160$11.27MShares unchanged; reported value increased 11.19%, and weight changed +0.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
Michelson Medical Research Foundation, Inc. · VANGUARD FTSE DEVELOPED ETF

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1965304","quarter":"2026Q2","cusip":"921943858"}

get_institutional_manager_history
{"cik":"1965304","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.